Introduction: The Etanercept Biosimilar Higher-Order Structure is one of the most critical attributes evaluated during biosimilar development because even subtle […]
Introduction Post-Approval Changes for Approved Biosimilars require a structured, science-driven comparability assessment conducted in accordance with the ICH Q5E framework
Post-Approval Changes for Approved Biosimilars: Comparability Requirements Under ICH Q5E Read More »
Introduction: Setting a therapeutic peptide API purity specification is one of the most consequential — and most frequently misjudged —
Introduction The regulatory framework governing Extrapolation of Indications in Biosimilar Approval is a well-established, science-driven approach that enables a biosimilar
PLGA Microsphere Formulation Development — Case Study Redesign :root{ –ink:#101d2b; –paper:#f6f5f1; –panel:#ffffff; –teal:#1b6e71; –teal-dim:#e4eeed; –amber:#b8802e; –amber-dim:#f4e9da; –slate:#57626e; –line:#e1ddd2; –line-dark:#28394a; }
Case Study: PLGA Microsphere Formulation Development for a 3-Month Depot Antipsychotic Read More »
Introduction: Bioequivalence study bioanalytical services are the laboratory backbone of every generic drug approval, formulation change, and lifecycle management submission
Introduction Nitrosamine Risk in Drug-Drug Combination Products has emerged as a significant toxicological challenge because combining multiple active pharmaceutical ingredients
Introduction Antisense Oligonucleotide-Peptide Conjugates have emerged as an advanced therapeutic platform designed to address the longstanding pharmacokinetic, biodistribution, and intracellular
Introduction: Nitrosamine leachables in blister packaging have become one of the most closely scrutinized contamination pathways in oral solid dosage
Introduction The structural characterization of biomolecular assemblies increasingly depends on Native Mass Spectrometry for Therapeutic Peptide Characterization, as it enables
